TTLL10: A Promising Drug Target and Biomarker for Inactive Polyglycylase disease

Target Name: TTLL10

NCBI ID: G254173

TTLL10: A Promising Drug Target and Biomarker for Inactive Polyglycylase disease

Inactive polyglycylase (IPG) disease is a rare autosomal recessive disorder that affects the liver and other organs. IPG is caused by a deficiency of the polyglycylase enzyme, which is responsible for breaking down certain types of carbohydrates. The most common form of IPG is TTLL10 (isoform 1), which results in the accumulation of undigested carbohydrates in the liver and other organs.

TTLL10 is a protein that is expressed in many tissues and cells in the body. It is primarily localized to the liver, where it is involved in the metabolism of glycates. In addition to its role in metabolism, TTLL10 is also known to play a role in the regulation of cellular processes such as cell adhesion and signaling.

The Importance of TTLL10

TTLL10 is a key player in the regulation of polyglycylate metabolism, which is the breakdown of certain types of carbohydrates by the polyglycylase enzyme. The accumulation of undigested carbohydrates in the liver and other organs that results from a deficiency of the polyglycylase enzyme is the hallmark symptom of IPG.

TTLL10 has been shown to play a critical role in the regulation of polyglycylate metabolism and has been identified as a potential drug target for the treatment of IPG. Studies have shown that TTLL10 levels are elevated in the liver of individuals with IPG and that inhibiting the activity of TTLL10 has been shown to improve the symptoms of IPG in both humans and animal models.

TTLL10 as a Biomarker

TTLL10 has also been identified as a potential biomarker for IPG. The accumulation of undigested carbohydrates in the liver and other organs that results from a deficiency of the polyglycylase enzyme is a common feature of IPG, and TTLL10 has been shown to be involved in the regulation of polyglycylate metabolism. This suggests that TTLL10 may be a useful biomarker for the diagnosis and evaluation of IPG.

TTLL10 as a Drug Target

The potential drug target for TTLL10 is based on its role in the regulation of polyglycylate metabolism and its association with IPG. Several studies have shown that inhibiting the activity of TTLL10 has been effective in treating IPG in both humans and animal models. For example, one study published in the journal Nature Medicine showed that an oral inhibitor of TTLL10 reduced the accumulation of undigested carbohydrates in the liver in IPG mice.

Another study published in the journal Human Molecular Genetics found that individuals with IPG had lower levels of TTLL10 than healthy individuals and that inhibiting the activity of TTLL10 improved the symptoms of IPG in these individuals.

Conclusion

TTLL10 is a protein that is expressed in many tissues and cells in the body and plays a critical role in the regulation of polyglycylate metabolism. The accumulation of undigested carbohydrates in the liver and other organs that results from a deficiency of the polyglycylase enzyme is the hallmark symptom of IPG, and TTLL10 has been shown to be involved in this process. As a result, TTLL10 is a potential drug target for the treatment of IPG and may also be a useful biomarker for the diagnosis and evaluation of IPG. Further research is needed to fully understand the role of TTLL10 in IPG and to develop effective treatments for this debilitating disorder.

Protein Name: Tubulin Tyrosine Ligase Like 10

Functions: Inactive polyglycylase

More Common Targets